HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer

National Taiwan University Hospital, Taipei

Columbia University Irving Medical Center, New York

Memorial Sloan Kettering Cancer Center, New York

Taipei Veterans General Hospital, Taipei

University of Pennsylvania, Philadelphia

Georgetown University Medical Center, Washington D.C.

Virginia Cancer Specialists, PC, Fairfax

Sarah Cannon and HCA Research Institute, Nashville

Chung Shan Medical University Hospital, Taichung

Henry Ford Cancer Institute, Detroit

Northwestern University Feinberg School of Medicine, Chicago

UCLA, Santa Monica

Taipei Medical University Hospital, Taipei

Yale University School of Medicine - Yale-New Haven Hospital, New Haven

Massachusetts General Hospital Cancer Center, Boston

Dana-Farber Cancer Institute, Boston

Dartmouth-Hitchcock Medical Center, Lebanon

National Hospital Organization Shikoku Cancer Center, Matsuyama

National Hospital Organization Kyushu Cancer Center, Fukuoka

National Hospital Organization Hokkaido Cancer Center, Sapporo

Kanagawa Cancer Center, Yokohama

Okayama University Hospital, Okayama

National Cancer Center Hospital, Chuo Ku

National Hospital Organization Iwakuni Clinical Center, Iwakuni-shi

Kindai University Hospital, Ōsaka-sayama

Shizuoka Cancer Center, Shizuoka

The Cancer Institute Hospital of JFCR, Tokyo

Seoul National University Hospital, Seoul

Yonsei University Health System - Severance Hospital, Seoul

Asan Medical Center, Seoul

Samsung Medical Center, Seoul